Guggenheim Reiterates Buy on Biomarin Pharmaceutical, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay has reiterated a 'Buy' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $110.
September 13, 2023 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst has reiterated a 'Buy' rating on Biomarin Pharmaceutical and maintained a price target of $110.
The reiteration of a 'Buy' rating by a Guggenheim analyst and the maintenance of a $110 price target indicates a positive outlook for Biomarin Pharmaceutical. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100